Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase

Cancer Gene Therapy

Volumn 18, Issue 6, 2011, Pages 390-398

  Parker, W B ^a   Allan, P W ^a   Waud, W R ^a   Hong, J S ^b   Sorscher, E J ^b  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

2 F 20 deoxyadenosine; 6 methylpurine 20 deoxyriboside; 9 b D arabinofuranosyl 2 fluoroadenine; adenine phosphoribosyltransferase; E. coli purine nucleoside phosphorylase; fludarabine

Indexed keywords

2' DEOXY 2 FLUOROADENOSINE; 6 METHYLPURINE 2' DEOXYRIBOSIDE; ADENINE PHOSPHORIBOSYLTRANSFERASE; DEOXYADENOSINE DERIVATIVE; FLUDARABINE PHOSPHATE; PRODRUG; PURINE NUCLEOSIDE PHOSPHORYLASE; RIBONUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CANCER CELL CULTURE; CONTROLLED STUDY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METABOLITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RNA SYNTHESIS; TUMOR XENOGRAFT;

ADENINE PHOSPHORIBOSYLTRANSFERASE; ANIMALS; CELL LINE, TUMOR; ESCHERICHIA COLI; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; PRODRUGS; PURINE NUCLEOSIDES; PURINE-NUCLEOSIDE PHOSPHORYLASE; TRANSPLANTATION, HETEROLOGOUS; VIDARABINE PHOSPHATE;

MUS;

EID: 79956105583     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.4     Document Type: Article

References (22)

1. Parker WB, King SA, Allan PW, Bennett Jr LL, Secrist III JA, Montgomery JA et al. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum Gene Ther 1997; 8: 1637-1644. (Pubitemid 28031581)
2. Parker WB, Allan PW, Hassan AEA, Secrist III JA, Sorscher EJ, Waud WR. Antitumor activity of 2-fluoro-2-deoxyade-nosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther 2003; 10: 23-29. (Pubitemid 36222073)
3. Hong JS, Waud WR, Levasseur DN, Townes TM, Wen H, McPherson SA et al. Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res 2004; 64: 6610-6615. (Pubitemid 39297921)
4. Martiniello-Wilks R, Dane A, Voeks DJ, Jeyakumar G, Mortensen E, Shaw JM et al. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that initates the development of human disease. J Gene Med 2004; 6: 43-54. (Pubitemid 40228002)
5. Ungerechts G, Springfield C, Frenzke ME, Lampe J, Johnston P, Parker WB et al. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 2007; 67: 10939-10947. (Pubitemid 350145923)
6. Tai CK, Wang W, Lai YH, Logg CR, Parker WB, Li YF et al. Enhanced efficiency of prodrug activation therapy by tumor-selectively replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther 2010; 17: 614-623.
7. Noker PE, Duncan GF, El Dareer SM, Hill DL. Disposition of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5-phosphate in mice and dogs. Cancer Treat Rep 1983; 67: 445-456. (Pubitemid 13106683)
8. Hersh MR, Kuhn JG, Phillips JL, Clark G, Ludden TM, Von Hoff DD. Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemother Pharmacol 1986; 17: 277-280. (Pubitemid 16070940)
9. Parker WB, Allan PW, Shaddix SC, Rose LM, Speegle HF, Gillespie GY et al. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol 1998; 55: 1673-1681. (Pubitemid 28223460)
10. Hughes BW, King SA, Allan PW, Parker WB, Sorscher EJ. Cell to cell contact is not required for bystander cell killing by E. coli purine nucleoside phosphorylase. J Biol Chem 1998; 273: 2322-2328. (Pubitemid 28069286)
11. Hughes BW, Wells AH, Bebok Z, Gadi VK, Garver Jr RI, Parker WB et al. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res 1995; 55: 3339-3345.
12. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973; 51: 1417-1423.
13. Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett Jr LL, Parker WB. Tumor cell bystander killing in colonic carcinoma utilizing the E. coli Deo D gene to generate toxic purines. Gene Ther 1994; 1: 233-238.
14. Dykes DJ, Abbott BJ, Mayo JG, Harrison Jr SD, Laster Jr WR, Simpson-Herren L et al. Development of human tumor xenografts for in vivo evaluation of new antitumor drugs. Contrib Oncol Basel, Karger 1992; 42: 1-22.
15. Montgomery JA, Hewson K. Analogs of 6-methyl-9-ß-D- ribofuranosylpurine. J Med Chem 1968; 11: 48-52.
16. Parker WB, Bapat AR, Shen JX, Townsend AJ, Cheng YC. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonu-cleotide reductase. Mol Pharmacol 1988; 34: 485-491.
17. Altaner C. Prodrug cancer gene therapy. Cancer Lett 2008; 270: 191-201.
18. Tiraby M, Cazaux C, Baron M, Drocourt D, Reynes JP, Tiraby G. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett 1998; 167: 41-49. (Pubitemid 28451607)
19. Adachi Y, Tamiya T, Ichikawa T, Terada K, Ono Y, Matsumoto K et al. Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine. Hum Gene Ther 2000; 11: 77-89. (Pubitemid 30044042)
20. Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60: 3813-3822. (Pubitemid 32204573)
21. Bennett EM, Anand R, Allan PW, Hassan AEA, McPherson DT, Parker WB et al. Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system. Chem Biol 2003; 10: 1173-1181. (Pubitemid 38042722)
22. Parker WB, Allan PW, Ealick SE, Sorscher EJ, Hassan AEA, Silamkoti AV et al. Design and evaluation of 5'-modified nucleoside analogs as prodrugs for and E. coli purine nucleoside phosphorylase mutant. Nucleosides Nucleotides Nucleic Acids 2005; 24: 387-392. (Pubitemid 41440615)